Two other studies have reported similar results: patients with tumours expressing high levels of VEGF-A have a shorter overall survival than those with tumours expressing low VEGF-A levels, and the impact of VEGF-A is not a combined effect with other markers of poor prognosis (Smith et al, 2000; Lim et al, 2003). The gene discussed is VEGFA; the disease is neoplasm.